Search Results for "Ondansetron Im"

22:35 EDT 2nd August 2015 | BioPortfolio

Matching Channels

None

Matching News

Better Delivery, PTV News: Mar 26, 2010

BioAlliance gets approval to market Ondansetron RapidFilm

Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film

Zuplenz is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) Nov...

Transfer of products from GlaxoSmithKline to Novartis

The following products have been transferred from GlaxoSmithKline to Novartis: Arzenna (ofatumumab); Atriance (nelarabine); Hycamtin (topotecan); Revolade (eltrombopag); Tafinlar (dabrafenib); Tyverb ...

[Articles] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

Addition of aprepitant to ondansetron with or without dexamethasone is effective for the prevention of chemotherapy-induced nausea and vomiting in paediatric patients being treated with moderately or ...

Galena Biopharma nets $35.7mm through public offering

Galena Biopharma Inc. (oncology) netted $35.7mm through the public sale of 24.4mm common shares at $1.56. Investors also received five-year warrants to buy 12.2mm shares at $2.08. Proceeds will fund c...

Robert Gardner Law Announces Resource Site for Patients Prescribed Zofran During Pregnancy

Minneapolis, MN (PRWEB) March 31, 2015 A new legal resource site has been established to aid patients and family members who may have been prescribed Zofran, or it’s generic versions of Onda...

Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fos...

Kelley/Uustal Now Accepting Zofran Birth Defect Cases

FORT LAUDERDALE, Fla., March 20, 2015 /PRNewswire/ -- Kelley/Uustal, a Florida-based law firm, announced that it is now accepting and investigating cases involving birth defects caused by Zofran....

Matching PubMed Articles

Comparison of ondansetron and meperidine for treatment of postoperative shivering: a randomized controlled clinical trial.

The involved neurotransmitter pathways in the postoperative shivering (POS) are poorly understood. Recently, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists have been reported to prevent POS. We in...

Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder.

Serotonin reuptake inhibitors (SRIs) are the mainstay in the treatment of obsessive-compulsive disorder (OCD). Patients who do not respond adequately to SRIs commonly receive augmentation therapy with...

Dystonic reaction associated with ondansetron administration in a patient with normal pressure hydrocephalus.

A 77-year-old female with normal pressure hydrocephalus underwent urgent revision of the abdominal component of a ventriculoperitoneal shunt. Upon emergence from an uneventful general anesthetic, the ...

Bioequivalence of Ondansetron Oral Soluble Film 8 mg (ZUPLENZ) and Ondansetron Orally Disintegrating Tablets 8 mg (ZOFRAN) in Healthy Adults.

Oral formulations of ondansetron are used to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. An oral soluble film formulation of ondansetron (OND OSF) was develope...

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine.

Background. Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy. We explored its effectiveness in patients with leukemia receivi...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement